Abstract:
Nanotechnology development started from 20th century. It has the ability to deliver a small
molecular weight drugs also the ability to targeting to cells and tissues by macromolecules such
as genes, peptides and proteins. A lot of problems are solved by the use of nanotechnology like
lipophilic drugs by formulating them as nanoparticles, poorly soluble drugs by decreasing the
drug reactions and improving bioavailability. Solid lipid nanoparticles (SLNs) are defined as
colloidal particles which is characterized by small particle size, ability to change surface
properties and large surface area that facilitates the bioavailability of poorly water soluble
molecules also improving the penetration of the drug into the skin and providing the stability.
Magnetic nanoparticles (MNPs) are a special type of NPs that is characterized by high magnetic
susceptibility which validate it to be used in biomedical application. The particle size should be
small and the MNPs must have a high magnetization to facilitate its motion in the blood vessels
with an external magnetic field. Zolmitriptan is a selective serotonin receptor agonist which is
effective in reducing migrane symptoms. The purpose of the study is to prepare supermagnetic
solid lipid nanostructure lipid carrier of Zolmitriptan to enhance its bioavailability and to develop
SLNs containing Zolmitriptan. The objectivities are achieving maximum bioavailability,
achieving better solubility and achieving controlled sustained release of the drug. In this study, 6
formulas were prepared with different ratios and were evaluated for their particle size with a
range of (205.8_ 469.5 d.nm) and zeta potential with a range of (-14.0_ -20 mv) and the
entrapment efficiency were (58%_55%).Formula number 4 were the best as it had the slowest
release.
